{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-006049","form_type":"8-K","ticker":"CRDF","cik":"0001213037","company_name":"Cardiff Oncology, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.092813+00:00","generated_at":"2026-06-18T14:22:15.429195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cardiff Oncology reports FY2022 cash of $105.3M; provides clinical updates for onvansertib","bullets":["Cash, cash equivalents, and short-term investments $105.3M at Dec 31, 2022; projected runway into 2025.","Total operating expenses $40.3M for FY2022, up $11.1M from FY2021; net cash used in operations $33.8M.","Phase 1b/2 mCRC trial: ORR 35% (n=48), median PFS 9.3 months; bevacizumab-naïve subgroup ORR 69%, mPFS 13.5 months.","Appointed Fairooz Kabbinavar as CMO, Tod Smeal as CSO, Charles Monahan as SVP Regulatory Affairs.","Upcoming data readouts: mPDAC and SCLC in Q2/Q3 2023; TNBC in Q4 2023/Q1 2024; ONSEMBLE mCRC randomized data in Q3/Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-006049","json":"https://secwatch.observer/filing/0001628280-23-006049.json","markdown":"https://secwatch.observer/filing/0001628280-23-006049.md","text":"https://secwatch.observer/filing/0001628280-23-006049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/0001628280-23-006049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/crdf-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:22:15.429195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1ed6d3bc63a863cb37eed0558bd99658601b5eb","claim":"Cardiff Oncology, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_excerpt":"On March 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the fourth quarter and fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023006049/0001628280-23-006049-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}